⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3292328 | 0.84 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL3663584 | 0.78 | — | — | |
| SCHEMBL8190613 | 0.78 | — | — | |
| SCHEMBL8447800 | 0.78 | — | — | |
| SCHEMBL8447798 | 0.78 | — | — | |
| SCHEMBL5751670 | 0.78 | — | — | |
| SCHEMBL30767272 | 0.77 | — | — | |
| SCHEMBL30767273 | 0.77 | — | — | |
| SCHEMBL21899343 | 0.75 | CDK2 (0.41) | — | |
| SCHEMBL22576285 | 0.75 | CDK2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025231152-A1 | COMPOUNDS AND METHODS FOR RESTORING BETA-ADRENERGIC RECEPTOR FUNCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-06 | — | — | WO | disclosed |
| US-20250051347-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals, Inc. (CN) | 2025-02-13 | — | — | US | disclosed |
| EP-4378936-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals Inc. (CN) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023151662-A1 | ANDROGEN RECEPTOR ACTIVITY REGULATOR AND USE THEREOF | 上海奕拓医药科技有限责任公司 | 2023-08-17 | — | — | WO | disclosed |
| CN-115677667-A | Bifunctional chimera heterocyclic compound and application thereof as androgen receptor degrading agent | 海创药业股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2023006097-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | 海创药业股份有限公司 | 2023-02-02 | — | — | WO | disclosed |
| WO-2023006097-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | 海创药业股份有限公司 | 2023-02-02 | — | — | WO | disclosed |
| US-11459336-B2 | Pyrazine carbamates and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-04 | — | — | US | disclosed |
| EP-3983072-A1 | PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | disclosed |
| CN-113950357-A | Pyrazine carbamates and their use as GluN2B receptor modulators | 詹森药业有限公司 | 2022-01-18 | — | — | CN | disclosed |
| WO-2020249796-A1 | PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| US-20200392155-A1 | PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | US | disclosed |